Antibody Therapeutics Xchange
- How to overcome the challenges of measuring and quantifying the specific antibody response in your animal or human model?
- What strategies can be implemented to leverage the over-expressed antibodies the animal or human produces naturally as a therapeutic or biomarker?
- How to overcome issues of downstream optimization sooner?
Director, Business Development
Anthony has been heading the business development at Rapid Novor for nearly 4 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™and NovorIg™ platforms with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a maker and in his spare time takes advantage of the Toronto HackLab to do biological research and other engineering projects.
- Target classes: native cell surface proteins, cancer glycans, HLA-presented epitopes: window into intracellular expression and modification
- A continuum of targets: lineage specific markers, TAAs, CTAs, neoantigens
- Primary targets and secondary targets for TME remodeling/escape from immune suppression
Chief Scientific Officer
Jonah Rainey holds a PhD in Biochemistry from Tufts University and completed postdoctoral training at the University of Wisconsin and the Salk Institute. He has engaged in discovery, research, and development of bispecific antibodies for 12 years. He is an inventor on several patents describing novel bispecific platforms and current clinical candidates that exploit these platforms. Jonah contributed to research and early development of multiple clinical candidates in phase 1 and 2, and led many advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Industry experience includes MacroGenics, MedImmune, MabVax, Oriole Biotech and Gritstone Oncology.
3:45pm – 4:45pm
- Epitope coverage and bins: At which stage(s) and how can we think about them?
- What are best methods for looking at epitopes in early hit discovery?
- Preferred epitopes for distinct MoAs (internalizers, ADCC-induction, agonists) – screening or design? What can we learn?
- Antibody sequence to epitope correlation – match or distant relation?
- In silico design of antibodies to target defined epitopes – future or fiction?
Director, Antibody Generation
Lore leads the Antibody Generation group at Bristol-Myers Squibb, which supports therapeutic programs across multiple therapeutic areas with sequence- and epitope diversified antibodies. She joined BMS from Boehringer Ingelheim, where she held several positions, leading teams and projects in Antibody Discovery, Early Development and Technology Management. She received her Ph.D. in molecular and cell biology from the German Cancer Center in Heidelberg, Germany.